📄 Description (English)
Vulnerability in the Oracle Life Sciences InForm product of Oracle Life Science Applications (component: IDM Authentication). Supported versions that are affected are 7.0.1.0 and 7.0.1.1. Easily exploitable vulnerability allows unauthenticated attacker with network access via HTTP to compromise Oracle Life Sciences InForm. Successful attacks require human interaction from a person other than the attacker. Successful attacks of this vulnerability can result in unauthorized update, insert or delete access to some of Oracle Life Sciences InForm accessible data as well as unauthorized read access to a subset of Oracle Life Sciences InForm accessible data and unauthorized ability to cause a partial denial of service (partial DOS) of Oracle Life Sciences InForm. CVSS 3.1 Base Score 6.3 (Confidentiality, Integrity and Availability impacts). CVSS Vector: (CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:L/A:L).
🤖 AI Executive Summary
CVE-2026-34323 is a medium-severity authentication bypass vulnerability in Oracle Life Sciences InForm versions 7.0.1.0 and 7.0.1.1 that allows unauthenticated network attackers to compromise the system through HTTP with user interaction. The vulnerability enables unauthorized data access (read, insert, update, delete) and partial denial of service. While no exploit is currently available and no patch exists, the easily exploitable nature and lack of authentication requirement pose significant risk to healthcare and pharmaceutical organizations in Saudi Arabia.
📄 Description (Arabic)
🤖 AI Intelligence Analysis Analyzed: May 17, 2026 07:20
🇸🇦 Saudi Arabia Impact Assessment
This vulnerability primarily impacts Saudi healthcare organizations, pharmaceutical companies, and clinical research institutions using Oracle Life Sciences InForm. High-risk sectors include: (1) Ministry of Health and affiliated hospitals conducting clinical trials, (2) Private healthcare providers (Dr. Sulaiman Al Habib, National Guard Health Affairs), (3) Pharmaceutical companies and contract research organizations (CROs) conducting drug development, (4) ARAMCO healthcare divisions managing employee health data. The authentication bypass could expose sensitive patient data, clinical trial information, and research data subject to GDPR and Saudi healthcare regulations. Secondary impact on government health agencies and SAMA-regulated healthcare financing entities.
🏢 Affected Saudi Sectors
Healthcare
Pharmaceutical
Clinical Research
Government Health Agencies
Private Hospitals
Contract Research Organizations
Medical Device Companies
Healthcare IT Services
🎯 MITRE ATT&CK Techniques
T1190 - Exploit Public-Facing Application
T1566 - Phishing (UI:R indicates user interaction required)
T1078 - Valid Accounts (authentication bypass)
T1110 - Brute Force (potential attack vector)
T1530 - Data from Cloud Storage
T1213 - Data from Information Repositories
T1565 - Data Manipulation
T1499 - Endpoint Denial of Service
⚖️ Saudi Risk Score (AI)
6.8
/ 10.0
🔧 Remediation Steps (English)
Immediate Actions:
1. Identify all systems running Oracle Life Sciences InForm versions 7.0.1.0 or 7.0.1.1 in your environment
2. Restrict network access to affected systems using firewall rules - limit HTTP/HTTPS access to trusted IP ranges only
3. Implement network segmentation to isolate InForm systems from general user networks
4. Enable enhanced logging and monitoring for all HTTP requests to InForm systems
5. Require multi-factor authentication at the application level as compensating control
Compensating Controls (until patch available):
6. Deploy Web Application Firewall (WAF) rules to detect and block suspicious authentication attempts
7. Implement reverse proxy with additional authentication layer in front of InForm
8. Monitor for indicators of compromise: unusual data access patterns, unauthorized modifications, session anomalies
9. Conduct user awareness training on phishing and social engineering (since UI:R indicates user interaction required)
10. Review and audit all recent data access logs for unauthorized activities
Detection Rules:
- Monitor for HTTP requests to InForm without valid authentication tokens
- Alert on data modification operations from unauthenticated sessions
- Track failed authentication attempts followed by successful data access
- Monitor for unusual geographic or IP-based access patterns
- Alert on bulk data export or deletion operations
Long-term:
11. Plan immediate upgrade to patched version when available
12. Contact Oracle support for security advisory and patch timeline
13. Evaluate alternative solutions if patch timeline is unacceptable
🔧 خطوات المعالجة (العربية)
الإجراءات الفورية:
1. تحديد جميع الأنظمة التي تعمل بإصدارات Oracle Life Sciences InForm 7.0.1.0 أو 7.0.1.1
2. تقييد الوصول إلى الأنظمة المتأثرة باستخدام قواعد جدار الحماية - حصر الوصول HTTP/HTTPS على نطاقات IP موثوقة فقط
3. تطبيق تقسيم الشبكة لعزل أنظمة InForm عن شبكات المستخدمين العامة
4. تفعيل السجلات المحسنة والمراقبة لجميع طلبات HTTP إلى أنظمة InForm
5. فرض المصادقة متعددة العوامل على مستوى التطبيق كإجراء تعويضي
الضوابط التعويضية (حتى توفر التصحيح):
6. نشر قواعد جدار تطبيقات الويب (WAF) للكشف عن محاولات المصادقة المريبة وحجبها
7. تطبيق وكيل عكسي مع طبقة مصادقة إضافية أمام InForm
8. مراقبة مؤشرات الاختراق: أنماط الوصول غير العادية للبيانات والتعديلات غير المصرح بها وشذوذ الجلسات
9. تدريب الموظفين على الوعي الأمني بشأن التصيد والهندسة الاجتماعية
10. مراجعة وتدقيق جميع سجلات الوصول الحديثة للأنشطة غير المصرح بها
قواعد الكشف:
- مراقبة طلبات HTTP إلى InForm بدون رموز مصادقة صحيحة
- تنبيهات على عمليات تعديل البيانات من جلسات غير مصرح بها
- تتبع محاولات المصادقة الفاشلة متبوعة بالوصول الناجح للبيانات
- مراقبة أنماط الوصول غير العادية بناءً على الموقع الجغرافي أو IP
- تنبيهات على عمليات تصدير أو حذف البيانات بكميات كبيرة
المدى الطويل:
11. التخطيط للترقية الفورية إلى الإصدار المصحح عند توفره
12. الاتصال بدعم Oracle للحصول على التنبيه الأمني وجدول التصحيح
13. تقييم الحلول البديلة إذا كان جدول التصحيح غير مقبول
📋 Regulatory Compliance Mapping
🟢 NCA ECC 2024
A.5.1.1 - Information Security Policies and Procedures
A.6.1.1 - Access Control Policy
A.6.2.1 - User Registration and De-registration
A.6.2.2 - User Access Rights Review
A.8.2.1 - User Authentication
A.8.2.3 - Password Management
A.9.2.1 - User Responsibility for Confidentiality
A.10.1.1 - Information Security Incident Procedures
A.12.4.1 - Event Logging
A.12.4.3 - Protection of Log Information
🔵 SAMA CSF
ID.AM-2: Software platforms and applications are inventoried
PR.AC-1: Identities and credentials are issued and managed
PR.AC-2: Physical access is managed
PR.AC-3: Remote access is managed
PR.AC-4: Access rights and privileges are managed
PR.PT-2: Removable media is protected and its use restricted
DE.AE-1: A baseline of network operations and expected data flows is established
DE.CM-1: The network is monitored to detect potential cybersecurity events
RS.AN-1: Notifications from detection systems are investigated
🟡 ISO 27001:2022
5.2 - Information Security Policies
6.2 - Information Security Risk Assessment
8.2 - Confidentiality and Integrity
8.3 - Access Control
8.4 - Cryptography
8.5 - Physical and Environmental Security
8.6 - Operations Security
8.7 - Communications Security
8.8 - System Acquisition, Development and Maintenance
8.9 - Supplier Relationships
8.10 - Information Security Incident Management
8.11 - Business Continuity Management
🟣 PCI DSS v4.0.1
1.1 - Firewall Configuration Standards
2.1 - Default Passwords
6.2 - Security Patches
7.1 - Access Control Implementation
8.1 - User Identification and Authentication
10.1 - Audit Trails
10.2 - User Access Logging
🔗 References & Sources 1